logo

AVAH

Aveanna Healthcare·NASDAQ
--
--(--)
--
--(--)
8.89 / 10
Outperform

AVAH's fundamental analysis is outstanding, with a comprehensive score of 8.89/10. Key drivers include top-quartile YoY growth in basic earnings per share (209.5%), diluted earnings per share (204.8%), and net cash flow from operating activities per share (15.6%). The stock ranks in the highest performance group for total profit growth (409.7%) and net profit attributable to shareholders (215.4%), indicating robust profitability. However, metrics like Net income-Revenue (-1.724) and Asset-MV (-0.501) fall into less favorable groups, suggesting potential valuation stretch and revenue scale considerations. Overall, the fundamental picture is strong but not without minor red flags.

Fundamental(8.89)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value1.02
Score1/3
Weight2.77%
1M Return0.59%
Net cash flow from operating activities per share (YoY growth rate %)
Value15.61
Score2/3
Weight6.54%
1M Return1.41%
Net income-Revenue
Value-1.72
Score0/3
Weight-0.92%
1M Return-0.21%
Basic earnings per share (YoY growth rate %)
Value209.52
Score3/3
Weight23.60%
1M Return4.75%
Total profit (YoY growth rate %)
Value409.67
Score3/3
Weight30.71%
1M Return6.14%
Net cash flow from operating activities (YoY growth rate %)
Value295.91
Score2/3
Weight13.17%
1M Return2.70%
Diluted earnings per share (YoY growth rate %)
Value204.76
Score3/3
Weight25.52%
1M Return5.10%
Asset-MV
Value-0.50
Score0/3
Weight-21.15%
1M Return-3.95%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value215.39
Score3/3
Weight20.24%
1M Return4.09%
Cash-MV
Value-0.45
Score1/3
Weight-0.46%
1M Return-0.11%
Is AVAH undervalued or overvalued?
  • AVAH scores 8.89/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 3.29% net margin, 88.38 P/E ratio, 165.42 P/B ratio, and 208.57% earnings growth, these metrics solidify its Outperform investment rating.